https://www.taxtmi.com/news?id=57058 A US trade measure imposes a 100% tariff on branded and patented pharmaceutical products from October 1, exempting products where the company "is building" a US manufacturing plant-defined as "breaking ground" or "under construction." The tariff conditions supply-chain decisions and investment planning by tying exemption eligibility to physical construction status. The announcement precipitated a sharp market reassessment of export-dependent pharma firms, heavy selling in pharma and IT sectors, index declines, and notable foreign institutional equity outflows as investors adjusted earnings and export-growth expectations. en-us Fri, 26 Sep 2025 17:01:03 +0530 Fri, 26 Sep 2025 17:01:03 +0530 TaxTMI RSS Generator https://www.taxtmi.com/news?id=57058 A US trade measure imposes a 100% tariff on branded and patented pharmaceutical products from October 1, exempting products where the company "is building" a US manufacturing plant-defined as "breaking ground" or "under construction." The tariff conditions supply-chain decisions and investment planning by tying exemption eligibility to physical construction status. The announcement precipitated a sharp market reassessment of export-dependent pharma firms, heavy selling in pharma and IT sectors, index declines, and notable foreign institutional equity outflows as investors adjusted earnings and export-growth expectations. News - Fri, 26 Sep 2025 17:01:03 +0530 https://www.taxtmi.com/news?id=57058